other material
confidence high
sentiment positive
materiality 0.85
Viridian's veligrotug Phase 3 THRIVE meets all endpoints; 70% proptosis responder rate vs 5% placebo (p<0.0001)
Viridian Therapeutics, Inc.\DE
- Proptosis responder rate 70% drug vs 5% placebo; mean reduction 2.9 mm vs 0.5 mm (p<0.0001).
- Complete diplopia resolution 54% vs 12%; CAS 0/1 achieved by 64% vs 18% (both p<0.0001).
- No treatment-related serious AEs; 5.5% placebo-adjusted hearing impairment rate; 4% discontinuation rate.
- THRIVE-2 enrollment complete; topline data year-end 2024; BLA submission on track for 2H 2025.
- Cash $571.4M as of June 30, 2024; runway into 2H 2026; VRDN-003 phase 3 REVEAL trials initiated.